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ABSTRACT
Background: There are no published studies that have
compared the medical costs of patients with seasonal and
perennial allergic rhinitis symptomatology.
Objectives: The objectives of this study were to develop
an algorithm for classifying patients into seasonal and
perennial groups based on their patterns of allergy med-
ication use and then compare the epidemiology and eco-
nomics of the two groups.
Methods: Data for the study were obtained from the
1996 to 1998 MarketScan databases containing linked
inpatient, outpatient, and pharmaceutical claims for
approximately 2 million covered lives annually. Patients
were classiﬁed into seasonal allergic rhinitis (SAR) or per-
ennial allergic rhinitis (PAR) groups based on their pat-
tern of allergy medication use over the course of 1 year
and then compared using descriptive methods.
Results: Seventy-nine percent of the total study sample
(80,534 allergy patients) was classiﬁed as SAR and 21%
as PAR. PAR patients were found to have higher mean
levels of allergy-related outpatient payments ($568 vs.
$471) and higher mean costs for second-generation anti-
histamines ($552 vs. $162). PAR patients also had
higher levels of comorbidities (asthma, sinusitis, depres-
sion, and migraine), higher numbers of concomitant
medications (multiple second-generation antihistamines,
nasal steroids, other antihistamines, asthma medications,
and ophthalmic decongestants), and more immunization
encounters.
Conclusions: Approximately 21% of allergic rhinitis
patients have perennial symptoms as reﬂected in their pat-
terns of medication use. Perennial patients have signiﬁ-
cantly higher allergy-related health-care costs and rates of
comorbidities and greater use of concomitant medica-
tions. These distinct clinical and resource use proﬁles may
have implications for therapy choices in the cost-effective
management of perennial allergic rhinitis patients.
Keywords: allergic rhinitis, perennial allergic rhinitis,
seasonal allergic rhinitis.
Background
Estimates of the prevalence of allergic rhinitis range
from 10% of the US population [1] to as high as
30% among adults and 40% among children [2].
Regardless of the exact ﬁgure, allergic rhinitis is the
most prevalent chronic allergic respiratory disease
[3] and is one of the most common chronic health
conditions in the United States [4,5]. Very little
information is available on the prevalence of peren-
nial allergic rhinitis, although Naclerio and Solo-
mon [6] note that 21% of allergic rhinitis patients
are bothered by their symptoms for at least
41 weeks per year.
Allergic rhinitis rarely results in hospitalization.
Nevertheless, its high prevalence results in substan-
tial direct medical costs. Using data from the 1987
National Health Interview Survey and the 1988
National Ambulatory Care Survey, McMenamin [7]
estimated that the direct health-care costs of treat-
ing allergic rhinitis were $1.16 billion in 1990 dol-
lars. Using data from the 1987 National Medical
Expenditure Survey, Malone et al. [8] estimated the
direct medical costs of allergic rhinitis to be $1.15
billion in 1994. Storms et al. [9], however, using
data from a nationwide sample of 15,000 house-
holds, estimated that the prescription and ofﬁce
visit costs associated with allergy was $3.5 billion.
Allergic rhinitis can be either seasonal or peren-
nial (i.e., year-round) in duration. Most studies of
allergic rhinitis do not distinguish between seasonal
allergic rhinitis (SAR) and perennial allergic rhinitis
(PAR)—either reporting on both conditions as
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“allergic rhinitis” or focusing speciﬁcally on SAR.
SAR and PAR are distinguished by the allergens that
trigger symptoms and by the varying duration and
time of year of these symptoms. SAR patients react
to outdoor allergens (pollens and fungal spores)
that ﬂuctuate during the year. Thus, symptoms
either occur or are increased during certain seasons.
PAR patients exhibit symptoms continuously or
intermittently throughout the year and are affected
by indoor allergens (house dust, dust mites, animal
dander, mold). PAR and SAR may coexist in the
same individual with symptoms increasing in sever-
ity during certain seasons.
Allergic rhinitis has been linked to a variety of
other conditions. Patients with allergic rhinitis often
experience fatigue, irritability, mood swings, and
cognitive disturbances [3]. A clinical trial reported
consistently lower health-related quality of life for
PAR patients than for healthy controls [10]. Specif-
ically, PAR takes its toll on sleep, social functioning,
and productivity; is associated with nonrhinitis
problems of thirst and fatigue; and includes practi-
cal problems of frequent nose blowing. Further-
more, untreated allergic rhinitis may lead to more
serious diseases in upper and lower airways. Aller-
gic rhinitis is often associated with asthma, sinusitis,
otitis media, and polyps [11]. An extensive body of
literature documents that allergic rhinitis and
asthma frequently coexist [3,12,13]. Although the
prevalence of asthma in the general population is
3% to 5%, asthma affects approximately 38% of
patients diagnosed with allergies [12] and, among
those patients diagnosed with asthma, 60% to 78%
have allergic rhinitis [13]. Not only do allergic rhin-
itis and asthma coexist, but asthma patients with
symptomatic rhinitis use more asthma medications
than do asthmatics without rhinitis [12]. It has been
postulated that comorbid allergic rhinitis may be
related to increased asthma severity. Similarly,
investigators have noted links between allergies
and sinusitis [14,15], otitis media [16], and other
conditions.
Despite the large literature on comorbidities in
the allergic rhinitis population, virtually nothing is
known about differences in the patterns of comor-
bidities between patients with SAR and those with
PAR. In addition to being a marker of disease sever-
ity, different patterns of comorbidities could have
substantial implications for the cost burden of ill-
ness associated with SAR and PAR.
This study provides important new information
on the epidemiology and economics of PAR and
SAR by examining the characteristics and health-
care use of patients with seasonal versus perennial
patterns of prescription allergy medication use pat-
terns. We ﬁrst present an algorithm for classifying
patients treated with a second-generation antihista-
mine into seasonal or perennial cohorts based upon
patient-level allergy prescription histories. Once this
classiﬁcation is accomplished, we conduct a detailed
retrospective analysis of concomitant medication
use, clinical proﬁle, and medical resource use pat-
terns of SAR and PAR patients.
Methods
Data Source
The analytic ﬁle used in this study was constructed
from the 1996 to 1998 MarketScan Fee-For-Service
and Encounter databases. The Private Pay Fee-For-
Service database contains the health-care experience
of privately insured individuals enrolled in several
types of health plans, including exclusive provider
organizations, preferred provider organizations,
point-of-service plans, and indemnity plans. The
Private Pay Encounter database contains the health-
care experience of individuals covered under fully
and partially capitated health plans. Together, the
MarketScan Fee-for-Service and Encounter data-
bases contain information on approximately two
million covered lives annually. Using unique patient
identiﬁers, outpatient pharmaceutical claims can be
linked with the inpatient services, inpatient admis-
sions, and outpatient claims ﬁles. The outpatient
pharmaceutical claims ﬁle provides information on
drugs used, therapeutic class, days of intended ther-
apy, number of units prescribed, and pharmacy
service payments.
Study Population
Patients were identiﬁed as having allergic rhinitis if
they had a minimum of 30 days of therapy on one
of the nondecongestant versions of the three leading
second-generation antihistamines (cetirizine, fex-
ofenadine, or loratadine). We could not rely on
identifying the study population by the ICD-9 code
477.xx because only 47% of patients who had
claims for these drugs also had that diagnosis code.
Many of these patients may have received a diag-
nosis of allergic rhinitis prior to 1996, which would
not be reﬂected in the claims data that we analyzed.
We recognize that cetirizine, fexofenadine, and
loratadine are also sometimes used to treat condi-
tions other than allergy (e.g., atopic eczema) but we
found very little evidence of these diagnoses in our
data.
Our methodology for identifying patients with
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allergic rhinitis differs from other studies in the
peer-reviewed literature. Most previous studies have
identiﬁed allergic rhinitis patients based on the pres-
ence of an allergic rhinitis diagnosis, either patient
self-report or physician coded [7,8]. However,
because we found that 47% of the patients with sec-
ond-generation antihistamine prescriptions lacked a
corresponding medical claim containing an allergic
rhinitis diagnosis we felt that excluding such a large
segment of the sample would dramatically underes-
timate allergic rhinitis prevalence, as well as poten-
tially introduce bias into our analysis. Thus, we
elected to select the study sample on the basis of
medication utilization, rather than diagnosis codes
alone.
Enrollment data and a claims-based proxy for
enrollment were used to identify whether patients
were continuously enrolled in their health plan for
the study period. Using the enrollment data availa-
ble for a subset of the population, we identiﬁed
patients who had a positive enrollment ﬂag
between January 1, 1996, and December 31, 1998.
For the rest of the sample, we coded patients as
continuously enrolled if they incurred service
claims before and during the ﬁrst quarter of the
study period as well as during and after the last
quarter of the study period. Patients who were not
continuously enrolled were excluded from the
study sample. After applying the continuous enroll-
ment, preperiod, and study-period criteria, 80,534
patients were included in the ﬁnal study sample
(Table 1).
Seasonal Allergic Rhinitis and Perennial Allergic 
Rhinitis Classiﬁcation
People with seasonal allergic rhinitis commonly
present with seasonal symptoms in the spring or fall
because SAR is caused by either mold spores or tree,
grass, or weed pollens. In general, trees pollinate in
the spring, grasses pollinate in the summer, and
weeds pollinate in the fall. The timing of these dif-
ferent seasons varies somewhat by region. Con-
versely, people with perennial allergic rhinitis
usually have allergy symptoms throughout the year.
PAR is most often due to sensitivity to dust, dust
mites, animal dander, or mold spores. Because of
the timing differences in the occurrence of symp-
toms for SAR and PAR patients, we were able to
classify patients according to the patterns of their
claims for allergy medication. We hypothesize that
PAR patients will have claims for allergy medica-
tions throughout the year, while SAR patients will
have claims for allergy medications predominantly
around pollen allergy seasons: April, May, and June
for the spring allergy season and August, September,
and October for the fall allergy season. We observe
that the empirical markers of allergy seasons indi-
cated by the patterns of claims over time differed by
region—a ﬁnding consistent with the geographic
variation in seasonality of allergens [17].
Patients were classiﬁed as having a seasonal
persistent allergy pattern if they had at least one
period of continuous therapy lasting a minimum of
45 days and fewer than eight prescriptions during
the 12-month follow-up period; those having
Table 1 Descriptive statistics for the entire sample population and by seasonal versus perennial allergic rhinitis status
Total sample
Type of allergic rhinitis
P value
Seasonal Perennial 
N % N % N %
Total number of patients 80,534 100.00 63,960 79.40 16,574 20.60
Mean age (years) in the
illness category
 40.3  39.3  44.1 <0.0001
Women 49,433 61.4 38,663 60.4 10,770 65.0 <0.0001
Region
Northeast 11,934 14.8  9971 15.6 1,963 11.8 <0.0001
North Central 33,217 41.2 25,558 40.0 7,659 46.2 <0.0001
South 25,906 32.2 20,891 32.7 5,015 30.3 <0.0001
West 8,733 10.8 6,971 10.9 1,762 10.6 0.3229
Unknown  744 0.9  569 0.9  175 1.1 0.0462
Type of beneﬁt plan
Basic/major medical plan  882 1.1  725 1.1  157 0.9 0.0401
Comprehensive plan 28,485 35.4 22,118 34.6 6,367 38.4 <0.0001
HMO 2,552 3.2 2,159 3.4  393 2.4 <0.0001
POS 7,103 8.8 5,703 8.9 1,400 8.4 0.0575
PPO 19,650 24.4 15,249 23.8 4,401 26.6 <0.0001
Other 21,862 27.1 18,006 28.2 3,856 23.3 <0.0001
Percentage that were
encounter plans
21,913 27.2 18,289 28.6 3,624 21.9 <0.0001
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4 months or less of prescription therapy and no
period of continuous therapy of at least 45 days
were classiﬁed as having a seasonal intermittent pat-
tern (Fig. 1). The two seasonal groups were com-
bined to form the SAR group.
Patients were classiﬁed as having a perennial per-
sistent allergy pattern if they had eight or more pre-
scriptions during the 12-month period following
initial treatment; those having more than 4 months
of prescription therapy and no period of continuous
therapy of at least 45 days were classiﬁed as peren-
nial intermittent (Fig. 1). The two perennial groups
were combined to form the PAR group. Although
our classiﬁcation method for patients with peren-
nial allergic rhinitis does not distinguish between
those patients who have year-long symptoms with
seasonal exacerbations from those without seasonal
exacerbations, it does enable us to compare the
characteristics and health-care use patterns of
patients with year-long symptoms to those with sea-
sonal symptoms alone, as indicated by patterns of
prescription allergy medication use.
Statistical Analyses
Chi-square tests were used to compare the distribu-
tions of categorical variables between the SAR and
PAR groups; two-tailed t tests were used to compare
mean visits and mean expenditures.
Results
Regional Distributions of Prescription Volume by 
SAR/PAR Status
After identifying SAR and PAR patients, we used
the regional deﬁnitions of the US Bureau of the Cen-
sus (Fig. 2) to analyze the distribution of allergy
prescription claims over a 12-month follow-up
period. As expected, the allergy medication claims
for SAR patients were concentrated during the
months between April and June (Fig. 3). There was
another, smaller spike in SAR allergy prescriptions
in September, but prescription counts fell in Octo-
ber, November, and December. In contrast, allergy
medication claims for PAR patients were distributed
evenly over the year.
Comparisons by SAR/PAR Status
Demographic and health insurance characteristics
of the SAR and PAR samples are reported in
Table 1. In both samples, the majority of the
patients were women but the proportion of women
was higher in PAR patients than SAR patients (65
vs. 60%, P < .0001). Among the ﬁve classiﬁcations
of health plans, a plurality of the patients (35.4%)
had comprehensive indemnity plans, followed by
preferred provider organizations (24.4%); both
types of health plans were more common among
PAR than SAR patients (P < .0001). PAR patients
tended to be older than SAR patients (mean age 44
years for PAR vs. 39 years for SAR, p < .0001).
Figure 1 Seasonal versus perennial classiﬁcation.
Figure 2 US Census regions and  and divisions.
Figure 3 Prescription patterns by region.
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Overall, the sample was concentrated in the
North Central and Southern regions, similar to the
distribution of the MarketScan population in gen-
eral. However, the distribution of SAR and PAR
patients differed across regions. The percentage of
the national SAR patient population located in the
Northeast was higher than that of PAR patients
(15.6 vs. 11.8%, P < .0001), lower in the North
Central (40.0 vs. 46.2%, P < .0001), higher in the
South (32.7 vs. 30.3%, P < .0001), and not statis-
tically different in the West. Within each region,
SAR patients dominated—ranging from 77% of the
allergic rhinitis population in the North Central
region to 84% in the Northeast.
We searched for indications of several  comor-
bid conditions of interest: asthma, depression,
migraine, otitis media, and sinusitis (Table 2).
Patients were classiﬁed as having comorbid condi-
tions if they had claims with ICD-9 codes associated
with the conditions during the 12-month study
period or in the 12 months prior to the index pre-
scription date. SAR patients were more likely to be
free of comorbidities than PAR patients (42.0 vs.
35.9%). The two groups were about equally likely
to have one comorbid condition (35.8% for SAR,
36.4% for PAR), but PAR patients had a higher
likelihood of having two or more comorbidities
(27.3 vs. 22.1%).
Prevalence rates of most comorbid conditions
varied signiﬁcantly by PAR/SAR status. We found
statistically signiﬁcant and higher rates of comor-
bidities among PAR patients relative to SAR
patients in asthma (21.6 vs. 14.8%, P < .0001),
sinusitis (45.7 vs. 41.1%, P < .0001), depression
(13.4 vs. 11.6%, P < .0001), migraine (6.1 vs.
5.5%, P < .0001), and nasal polyps (0.5 vs. 0.4%,
P < .0303). Only otitis media did not have signiﬁ-
cantly different rates in the SAR and PAR samples.
Patients were coded as taking a concomitant
medication of interest if they had at least one claim
for those medications that overlapped with a pre-
scription for one of the three-second generation
antihistamines during the study period (Table 3 and
Fig. 4). The window for overlap was deﬁned as the
prescription date for the study drug plus the number
of days of therapy plus 30 days. We did this to
account for small gaps in therapy that might lead
one to conclude that patients were not being treated
with concomitant medications when, in fact, the
gaps were due to delays in reﬁlls. A signiﬁcantly
higher percentage of PAR patients than SAR
patients had claims for one or more of the concom-
itant medications (68.4 vs. 46.8%). More SAR than
Table 2 Comorbidities among patients with allergic rhini-
tis, by seasonal versus perennial allergic rhinitis status
Type of allergic rhinitis (%)
P value
Seasonal
(N = 63,960)
Perennial  
(N = 16,574)
Number of comorbidities
0 42.0 35.9
1 35.8 36.4
2 16.8 20.2
3 4.5 6.6
4 0.7 0.9
5 0.1 0.1
Chi-square <0.0001
Presence of comorbid conditions
Asthma 14.8 21.6 <0.0001
Sinusitis 41.1 45.7 <0.0001
Otitis media 13.5 13.6 0.6574
Depression 11.6 13.4 <0.0001
Migraine 5.5 6.1 <0.0001
Nasal polyps 0.4 0.5 0.0303
Table 3 Use of concomitant medications among patients with allergic rhinitis, by seasonal versus perennial allergic rhinitis
status
Type of allergic rhinitis (%) 
P value
Seasonal
(N = 63,960)
Perennial 
(N = 16,574) 
n % n %
Number of concomitant medications
0 34,027 53.2 5,237 31.6
1 22,514 35.2 6,945 41.9
2 6,588 10.3 3,696 22.3
3 895 1.4 713 4.3
Chi-square <0.0001
Use of medications of interest
One second-generation antihistamine 55,581 86.9 13,508 81.5 <0.0001
More than one second-generation antihistamine 8,443 13.2 3,066 18.5 <0.0001
Second-generation antihistamines with nasal steroids 20,083 31.4 3,066 50.2 <0.0001
Second-generation antihistamine with other antihistamines 6,716 10.5 3,033 18.3 <0.0001
Second-generation antihistamine with asthma medications 11,257 17.6 5,072 30.6 <0.0001
Second-generation antihistamines with ophthalmic decongestants 128 0.2 33 0.2 0.0291
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PAR patients used only one second-generation anti-
histamine during the 12-month study period (86.9
vs. 81.5%, P < .0001). A higher percentage of PAR
patients than SAR patients used second-generation
antihistamines with nasal steroids (50.2 vs. 31.4%,
P < .0001), with asthma medications (30.6 vs.
17.6%, P < .0001), or with other antihistamines
(18.3 vs. 10.5%, P < .0001).
PAR patients also tended to use more allergy-
related services and had higher allergy-related pay-
ments (Table 4 and Fig. 5). Table 5 indicates that
PAR patients on average had more allergy-related
outpatient visits than SAR patients (15.1 vs. 10.0,
P < .0001), as well as more immunization visits for
allergy desensitization (22.1 vs. 17.8, P < .0001).
Mean immunization visits exceed mean allergy-
related outpatient visits for the PAR and SAR
groups because these means were calculated for
service utilizers only. PAR patients also had higher
average total payments for allergy-related outpa-
tient visits ($568 vs. $471, P < .0001). Not surpris-
ingly, PAR patients had higher average payments for
the three second-generation antihistamines ($531
vs. $162, P < .0001).
Comment
The seasonal claims patterns varied by region,
although the strong seasonality of claims overall
suggests that our method of identifying SAR and
PAR patients was sound. The volume of SAR pre-
scription claims peaked in the spring and with a
smaller increase in the early fall, offering face valid-
ity to the classiﬁcation algorithm. The spring spike
in prescription volumes was especially pronounced
in the Northeast and the West. The apparent fall
spike in prescription volume among SAR patients in
the North Central region is actually due to lower
volume in the spring allergy season relative to other
regions. The lower spring volume exaggerates the
spike in the fall. In both the Northeast and North
Central regions SAR prescription volume declines in
the winter months.
The allergy seasons in the Northeast and North
Central appeared to lag those in the South and West
by about 1 month. The spring allergy season in the
West and South appeared to start in March and
peak in April. Although there was some evidence
that prescriptions began to increase in March for
SAR patients in the Northeast and North Central
regions, prescription activity there accelerated
strongly in April and peaked in May.
In contrast to the SAR graphs, the distribution of
PAR prescriptions is not only remarkably constant
across months but also across regions (Fig. 3). Both
results indicate that the prescriptions of PAR
Figure 4 Concomitant medications.
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Table 4 Health-care utilization and expenditures among patients with allergic rhinitis, by seasonal versus perennial allergic
rhinitis status
Allergy-related health-care utilization and expenditures
Type of allergic rhinitis
P value
Seasonal Perennial
N Mean Median N Mean Median
Number of allergy-related outpatient visits 10,427 10.0 2.0 3,867 15.1 9.0 <0.0001
Number of immunization visits for allergy desensitization 5,273 17.8 15.0 2,500 22.1 20.0 <0.0001
Total payments for allergy-related outpatient visits 10,353 $471 $283 3,850 $568 $403 <0.0001
Total payments for fexofenadine, loratadine, and cetirizine 63,960 $162 $115 16,574 $531 $552 <0.0001
Total payments for nasal steroids 22,597 $98 $66 8,122 $182 $135 0.0001
Figure 5 Total allergy-related payments.
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patients are insensitive to the timing of allergy sea-
sons—a ﬁnding consistent with properly classifying
patients into the SAR and PAR categories.
After assigning patients to the SAR or PAR cate-
gories we found a greater incidence of comorbid
conditions of interest and higher health-care use
and allergy-related expenditures for PAR patients
relative to SAR patients. Since expenditures were
measured using total payments, differences in
allergy-related payments between PAR and SAR
patients reﬂect the perspective of third party payers.
One possible explanation for the observed differ-
ences in health-care use and allergy-related expendi-
tures between the SAR and PAR groups is differences
in diagnostic procedures associated with the two cat-
egories of allergic rhinitis. SAR and PAR are diag-
nosed by a combination of clinical tests and patient
medical history. The cyclic nature of SAR symptoms
enables relative ease of identiﬁcation. In contrast, the
overlap of PAR symptoms with chronic sinusitis
and vasomotor rhinitis may complicate detection.
In general, the greater difﬁculty in diagnosing PAR
would be expected to require more extensive clini-
cal testing to conﬁrm the perennial diagnosis, to
uncover allergens, and to guide treatment [2]. In
turn, this more extensive clinical testing would be
expected to result in higher diagnostic costs.
A second potential explanation for the observed
differences in health-care resource use and allergy-
related expenditures between the SAR and PAR
groups is simply that the therapies used to treat
allergic rhinitis are used in greater quantities by
patients with PAR than those with SAR. The cost of
second-generation antihistamine therapy for PAR
patients was comparable to the cost associated with
outpatient visits. However, second-generation anti-
histamine costs for PAR patients were more than
three times those for SAR patients. There are
numerous pharmaceutical treatments available to
combat the symptoms of allergic rhinitis including
decongestants to relieve nasal congestion and pru-
ritus of the eye; antihistamines to relieve sneezing,
itching, and prevention of nasal congestion prior to
attack; and corticosteroid nasal sprays to reduce
inﬂammation. The year-round nature of PAR is
likely to increase expenses for all types of therapy
because patients experience symptoms more often.
The ﬁndings are consistent with PAR patients
having a greater average disease severity than SAR
patients. This possibility has signiﬁcant economic
implications. Several studies have estimated sub-
stantial economic costs from allergies and the treat-
ment of allergy symptoms with ﬁrst-generation
antihistamines [7–9,18]. Storms et al. [9] estimated
that direct allergy-related medical costs for prescrip-
tions and outpatient visits were $3.5 billion.
Estimates of the direct medical costs associated
with allergic rhinitis, however, almost surely under-
state the economic burden of the condition. A
number of studies have shown that allergic rhinitis
is frequently comorbid with other conditions [3,11–
13]. This pattern of comorbid conditions was found
in the current study as well. Although we did not
ﬁnd evidence of a substantial comorbidity of aller-
gic rhinitis with otitis media, this result was
expected because we examined only solid oral dos-
age forms of medications. As a result, patients
treated with pediatric forms of the medications
were not included in our sample. Moreover, it was
found that the prevalence of comorbidities was
higher among the PAR group than the SAR group
(Table 2). For example, the prevalence of diagnosed
asthma was 21.6% in the PAR group and 14.8% in
the SAR group. The higher prevalence of certain
comorbidities among PAR patients suggests that,
not only their allergy-related costs, but also their
total direct medical costs, will be greater than those
of SAR patients. Crystal-Peters et al. [19] found that
treatment for allergic rhinitis can reduce emergency
room use and hospitalizations for patients with
comorbid asthma. Thus, the economic implications
of important comorbidities with allergic rhinitis,
and how these implications may vary for SAR and
PAR patients, are areas in need of further study.
Collis and Pellegrini [20] report that as many as
75% of workers with allergies are either absent
from work or perform less productively at work for
2 or more weeks per year. Studies of the economic
impacts of allergic rhinitis, however, have implicitly
assumed that the impacts are conﬁned to spring and
fall allergy seasons. Our algorithm resulted in 21%
of patients being classiﬁed as PAR patients. For
these patients, the potential economic implications
could be year-long, suggesting that previous studies
may have substantially underestimated the eco-
nomic implications of allergic rhinitis and the
higher indirect costs incurred when ﬁrst-generation
antihistamines are utilized.
Findings from this study should be evaluated in
light of several potential limitations. We have not
attempted to identify those patients who have both
PAR and SAR. These patients would have been clas-
siﬁed as per our algorithm into the PAR group.
Identifying patients with both PAR and SAR would
require clinical and diagnostic information unavail-
able to us in the claims data. It is not possible to
distinguish perennial allergic rhinitis from nonall-
ergic rhinitis or their combination without the
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patient’s medical history and skin tests. Neverthe-
less, we feel that the prescription-based algorithm
for classifying patients is useful for distinguishing
between patients with seasonal versus perennial
symptomotology. Future work that attempts to
identify patients with both PAR and SAR would be
helpful in arriving at improved prevalence estimates
for the two populations.
The database analyzed in this study, although
very large, is not necessarily nationally representa-
tive. The health-care claims contained in the data-
base represent the health-care experience of
employees or their dependents primarily of Fortune
200 companies. As such, the health beneﬁt coverage
that these individuals have is relatively generous
compared to the national norm. Moreover, the geo-
graphic distribution of the individuals represented
in the claims differs somewhat from the geographic
distribution of the US population. This could affect
the relative balance of SAR and PAR patients iden-
tiﬁed by our algorithm if the geographical distribu-
tion of patients in our analysis differs from the
national distribution of the population in regions
with strong allergy seasons.
This article uses prescriptions and prescription
reﬁlls to identify patients likely to have allergic rhin-
itis. This approach represents an alternative to rely-
ing on diagnosis codes to identify allergic rhinitis
patients but it has its strengths and weaknesses. Its
primary strength is that it likely to capture nearly
everyone with moderate to severe allergic rhinitis
symptoms. In our data, we found that patients hav-
ing a series of prescriptions indicative of allergic
rhinitis often did not have a diagnosis code for the
condition in their medical claims. There are several
possible reasons for this—in particular, that these
patients may have received an allergic rhinitis diag-
nosis prior to the study period. As a consequence, to
rely on ICD-9 codes could result in a substantial
undercount of patients. The pattern of missing data
would probably be unbalanced as well. SAR
patients experience symptoms in fewer months per
year and thus would be less likely to receive an aller-
gic rhinitis diagnosis than PAR patients.
Yet there is no bright line between PAR and SAR
in terms of prescriptions patterns. To help distin-
guish between them, we required that patients clas-
siﬁed as having SAR needed to have at least one
45-day period of therapy but less than 8 months of
therapy in total over the course of a year. The results
in Fig. 3 imply that the algorithm worked reasona-
bly well: the PAR patients have very steady levels of
prescriptions in every month, whereas the SAR
patients show strong seasonality in prescription use.
Although use of inhaled corticosteroids and
other drugs are also used to treat allergic rhinitis, in
the absence of an associated diagnosis code for
allergic rhinitis, we would run the danger of includ-
ing patients with other conditions for which these
drugs are frequently used (e.g., asthma) in our SAR/
PAR categorizations. In contrast, during the time
period of this study second-generation antihista-
mines were indicated only for allergic rhinitis. The
estimated prevalence rates for the allergic rhinitis
group identiﬁed in this fashion is approximately
10%. This is the same as that obtained from recent
estimates from the National Health Interview
Survey.
A related issue is the reliability of diagnosis codes
for identifying the presence of comorbidities. Just as
allergic rhinitis diagnoses were apparently missing
for a substantial proportion of the observations, so
too may diagnoses for various comorbidities be
missing. Since SAR and PAR patients are both
observed for a 1-year period in the study there is no
apparent reason to expect that diagnosis codes
indicative of comorbidities would be differentially
missing for SAR versus PAR patients. However, it is
likely that the degree of comorbidity is understated
for both groups.
This study presents data on the epidemiology and
health-care resource use of patients with seasonal or
perennial patterns of prescription use. Patients with
seasonal patterns of allergy prescription reﬁlls had
different demographic characteristics, clinical pro-
ﬁles, and prescription patterns than patients with
perennial reﬁll patterns. Perennial patients had a
higher number of allergy-related visits, higher
allergy-related expenditures, and greater use of con-
comitant medications than seasonal patients. Peren-
nial patients were also found to have a greater
incidence of comorbid conditions (asthma, sinusitis,
depression, and migraine) than seasonal patients. In
particular, higher proportions of perennial patients
than seasonal patients used second-generation
antihistamines with nasal steroids or with other
antihistamines. Such differences in the clinical char-
acteristics and health-care use have important
implications for the choice of therapy and cost of
treating seasonal and perennial patients.
This study was supported by Pﬁzer.
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